What can target kidney fibrosis?
- PMID: 28391346
- DOI: 10.1093/ndt/gfw388
What can target kidney fibrosis?
Abstract
Fibrosis, a characteristic of all chronic kidney diseases, is now recognized to be an independent predictor of disease progression. Deposition of pathological matrix in the walls of glomerular capillaries, the interstitial space and around arterioles both predicts and contributes to functional demise of the nephron and its surrounding vasculature. Recent identification of the major cell populations of fibroblast precursors in the kidney interstitium as pericytes and tissue-resident mesenchymal stem cells, and in the glomerulus as podocytes, parietal epithelial and mesangial cells, has enabled the study of the fibrogenic process in much greater depth directly in the fibroblast precursors. These cells are not only matrix-producing cells, but are also important innate immune surveillance cells that regulate the inflammatory process, exacerbate tissue damage by release of radicals and cytokines, and contribute to parenchymal and microvascular dysfunction by aberrant wound-healing responses. Innate immune signaling in fibroblasts and their precursors is intimately intertwined with the process of fibrogenesis. In addition, genomic and genetic studies also point to defective responses in loci close to genes involved in solute transport, metabolism, autophagy, protein handling and vascular homeostasis, principally in the epithelium and endothelium, as upstream drivers of the fibrotic process, indicating that cellular crosstalk is vital for development of fibrosis. As we move beyond TGFβ inhibition as a central target for fibrosis, targeting innate immune signaling and metabolic dysfunction appear increasingly tenable alternative targets for novel therapies.
Keywords: anti-fibrotics; clinical trials; innate immunity; metabolism.
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Similar articles
-
From inflammation to renal fibrosis: A one-way road in autoimmunity?Autoimmun Rev. 2024 Apr;23(4):103466. doi: 10.1016/j.autrev.2023.103466. Epub 2023 Oct 15. Autoimmun Rev. 2024. PMID: 37848157 Review.
-
[Identification of Biomarkers for Tubular Injury and Interstitial Fibrosis in Chronic Kidney Disease].Yakugaku Zasshi. 2017;137(11):1355-1360. doi: 10.1248/yakushi.17-00150. Yakugaku Zasshi. 2017. PMID: 29093371 Review. Japanese.
-
Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition.Hum Pathol. 2009 Oct;40(10):1365-76. doi: 10.1016/j.humpath.2009.02.020. Epub 2009 Aug 19. Hum Pathol. 2009. PMID: 19695676 Review.
-
Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.Am J Physiol Cell Physiol. 2013 Apr 1;304(7):C591-603. doi: 10.1152/ajpcell.00414.2012. Epub 2013 Jan 16. Am J Physiol Cell Physiol. 2013. PMID: 23325411 Free PMC article. Review.
-
Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis.Curr Mol Med. 2005 Aug;5(5):467-74. doi: 10.2174/1566524054553478. Curr Mol Med. 2005. PMID: 16101477 Review.
Cited by
-
Expression Profiling of Fibroblasts in Chronic and Acute Disease Models Reveals Novel Pathways in Kidney Fibrosis.J Am Soc Nephrol. 2019 Jan;30(1):80-94. doi: 10.1681/ASN.2018060644. Epub 2018 Dec 13. J Am Soc Nephrol. 2019. PMID: 30545984 Free PMC article.
-
Rhein Improves Renal Fibrosis by Restoring Cpt1a-Mediated Fatty Acid Oxidation through SirT1/STAT3/twist1 Pathway.Molecules. 2022 Apr 6;27(7):2344. doi: 10.3390/molecules27072344. Molecules. 2022. PMID: 35408745 Free PMC article.
-
Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications.Front Pharmacol. 2018 Dec 19;9:1488. doi: 10.3389/fphar.2018.01488. eCollection 2018. Front Pharmacol. 2018. PMID: 30618774 Free PMC article. Review.
-
Therapeutic silencing of SMOC2 prevents kidney function loss in mouse model of chronic kidney disease.iScience. 2021 Sep 29;24(10):103193. doi: 10.1016/j.isci.2021.103193. eCollection 2021 Oct 22. iScience. 2021. PMID: 34703992 Free PMC article.
-
Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.Kidney Blood Press Res. 2018;43(2):329-349. doi: 10.1159/000487902. Epub 2018 Mar 6. Kidney Blood Press Res. 2018. PMID: 29529602 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials